ProFunds Biotechnology UltraSector Fund Investor Class (BIPIX)

67.58
Net Asset Value
-0.56%
1 Day
+8.18%
Year-to-Date
Overall Morningstar Rating
Trading--leveraged equity
Style or Category
No Load
Sales Expenses
1.45%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks daily investment results- before fees and expenses- that correspond to one and one-half times (1.5x) the daily performance of the Dow Jones U.S. BiotechnologySM Index. The fund invests in securities and derivatives that the adviser believes- in combination- should have similar daily return characteristics as one and one-half times (1.5x) the daily return of the index. The index measures the performance of the biotechnology sector of the U.S. equity market. It is non-diversified.

Performance

1 month-0.53% 3 years+1.57%
3 months+12.76% 5 years+26.10%
1 year+31.08% Since inception+7.81%
Data through --

Peer Comparisonvs. Trading--leveraged equity

 BIPIXCategory
Performance 5-yr return+26.10%+16.48%
Expense ratio1.45%2.01%
Risk 5 year sharpe ratio0.95--
Net assets$316.9M$103.7M
Average market cap$53.4B--
Average P/E18.2--
Portfolio turnover14%14%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyProFunds
Fund manager & tenureMichael Neches / 4 Years
Minimal initial investment$15,000.00
Minimum IRA investment--

Holdings

U.S. stock71.51%
Cash28.47%
Other0.02%
International stock0.00%
Fixed income0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ABBV AbbVie12.76%
AMGN Amgen11.34%
GILD Gilead Sciences8.68%
CELG Celgene7.00%
BIIB Biogen5.84%
VRTX Vertex Pharmaceuticals Inc3.27%
REGN Regeneron Pharmaceuticals2.74%
ILMN Illumina Inc2.66%
ALXN Alexion Pharmaceuticals Inc2.37%
INCY Incyte Corp1.71%